Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage

SIM0609 Doses First Patient in Phase I Clinical Study at Peking University Cancer Hospital

SIM0237 Phase I NMIBC Data Released in an Oral Presentation at SIU2025

Simcere Zaiming and NextCure Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States

SIM0609, Simcere Zaiming’s CDH17-targeting ADC is approved by the U.S. FDA to enter clinical trials

Achieving Quality Sleep and improving Daytime Function – Daridorexant Launch Celebrated at the 2025 China Sleep Medicine Development Forum

New-generation anti-insomnia drug Daridorexant issues China's first prescription, ushering in a new era of scientific sleep

New Drug Application (NDA) for Pediatric Influenza Antiviral Innovative Drug Deunoxavir Marboxil

New Sleep Medication Significantly Improves Multiple Sleep Parameters: Phase III Clinical Data of Daridorexant in China Published in SLEEP

Simcere Zaiming’s Polθ Inhibitor SIM0508 Obtains New IND Approval for Combination Use with Olaparib